Stock Research: ANI Pharma

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

ANI Pharma

NasdaqGM:ANIP US00182C1036
89
  • Value
    25
  • Growth
    84
  • Safety
    Safety
    79
  • Combined
    77
  • Sentiment
    88
  • 360° View
    360° View
    89
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

ANI Pharmaceuticals, Inc. is a biopharmaceutical company that develops, manufactures, and commercializes therapeutics. It operates in the biopharmaceutical industry, with a focus on rare disease conditions and branded pharmaceutical products. The company's operations are primarily within the United States. In the last fiscal year, the company had a market cap of $1,379 million, profits of $364 million, and revenue of $614 million, with 897 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 89 (better than 89% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock ANI Pharma are very positive. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for ANI Pharma. The consolidated Value Rank has an attractive rank of 79, which means that the share price of ANI Pharma is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 79% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 84, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 88. But the company’s financing is risky with a Safety rank of 25. This means 75% of comparable companies have a safer financing structure than ANI Pharma. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 30-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
79 53 42 61
Growth
84 59 79 85
Safety
Safety
25 69 55 36
Sentiment
88 80 96 34
360° View
360° View
89 88 93 60
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
91 83 76 17
Opinions Change
86 50 83 92
Pro Holdings
n/a 36 74 49
Market Pulse
53 91 48 30
Sentiment
88 80 96 34
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
79 53 42 61
Growth
84 59 79 85
Safety Safety
25 69 55 36
Combined
77 76 73 73
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
64 70 68 87
Price vs. Earnings (P/E)
46 55 44 56
Price vs. Book (P/B)
34 42 39 46
Dividend Yield
86 1 1 1
Value
79 53 42 61
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
63 83 41 77
Profit Growth
66 53 98 35
Capital Growth
53 30 37 59
Stock Returns
92 49 77 91
Growth
84 59 79 85
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
24 47 38 40
Refinancing
48 63 77 41
Liquidity
37 57 40 44
Safety Safety
25 69 55 36

Similar Stocks

Discover high‑ranked alternatives to ANI Pharma and broaden your portfolio horizons.

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Cognizant Technology

NasdaqGS:CTSH
Country: USA
Industry: IT Consulting & oth. Services
Size: X-Large
Full Stock Analysis

TEGNA

NYSE:TGNA
Country: USA
Industry: Broadcasting
Size: Medium
Full Stock Analysis

PriceSmart

NasdaqGS:PSMT
Country: USA
Industry: Hypermarkets, Super Centers
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.